PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Atacicept→

Atacicept PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
845264-92-8
Molecular formula
C3104H4788N856O950S44
Molecular weight
70708.13 g/mol
Drug class
TACI-Fc fusion proteindual B-lymphocyte stimulator (BLyS/BAFF) and APRIL inhibitor biologic
Mechanism of action
A soluble fusion protein comprising the extracellular domain of TACI linked to an Fc region. It binds and neutralises BLyS (BAFF) and APRIL, reducing survival and activation signals for B cells and antibody-producing plasma cells.
Indications / reported uses
  • Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression under the US FDA accelerated approval for atacicept-vymj (Trutakna, initial approval 2026). Long-term effect on kidney-function decline was not established in the accelerated-approval label; consult current product information.

Sources: US DailyMed — TRUTAKNA prescribing information, updated July 6 2026 · US FDA label — TRUTAKNA · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Atacicept PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Atacicept Permitted Daily Exposure (PDE) report (the Atacicept PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Atacicept Occupational Exposure Limit (OEL) report (the Atacicept OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.